Funding
Jan 15, 2026
Bioscibex has received strategic support from Kickfund as it prepares to launch its flagship bioreactor, SW1NGO, in mid-2026. The funding and guidance will help finalize industrialization, implement quality systems, and execute go-to-market plans, strengthening the company’s path to commercialization and global expansion.
Bioscibex, has secured strategic backing from Kickfund, a leading initiative supporting post–Venture Kick startups in Switzerland. The support comes at a crucial stage as Bioscibex prepares for the commercial launch of its flagship product, SW1NGO, planned for mid-2026.
Kickfund provides both essential funding and strategic guidance, helping startups bridge the critical phase between early validation and market entry. For Bioscibex, this support will accelerate the implementation of quality systems, finalize the industrialization of its bioreactors, and drive biopharma go-to-market strategies, ensuring a smooth and successful launch. The addition of Kickfund’s resources and expertise strengthens Bioscibex’s ability to bring this innovative solution to biopharmaceutical companies worldwide, reinforcing Switzerland’s position as a hub for life sciences innovation.
